- Home
- ZYME vs PRTA Comparison
ZYME vs PRTA Comparison
Compare ZYME & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- PRTA
- Stock Information
- Founded
- ZYME 2003
- PRTA 2012
- Country
- ZYME United States
- PRTA Ireland
- Employees
- ZYME N/A
- PRTA N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- ZYME Health Care
- PRTA Health Care
- Exchange
- ZYME Nasdaq
- PRTA Nasdaq
- Market Cap
- ZYME 846.1M
- PRTA 809.8M
- IPO Year
- ZYME 2017
- PRTA N/A
- Fundamental
- Price
- ZYME $11.31
- PRTA $7.43
- Analyst Decision
- ZYME Buy
- PRTA Buy
- Analyst Count
- ZYME 6
- PRTA 9
- Target Price
- ZYME $19.50
- PRTA $51.71
- AVG Volume (30 Days)
- ZYME 553.2K
- PRTA 1.4M
- Earning Date
- ZYME 05-08-2025
- PRTA 05-08-2025
- Dividend Yield
- ZYME N/A
- PRTA N/A
- EPS Growth
- ZYME N/A
- PRTA N/A
- EPS
- ZYME N/A
- PRTA N/A
- Revenue
- ZYME $93,384,000.00
- PRTA $137,935,000.00
- Revenue This Year
- ZYME $26.29
- PRTA N/A
- Revenue Next Year
- ZYME $75.78
- PRTA $131.71
- P/E Ratio
- ZYME N/A
- PRTA N/A
- Revenue Growth
- ZYME 85.05
- PRTA 54.55
- 52 Week Low
- ZYME $8.21
- PRTA $8.00
- 52 Week High
- ZYME $17.70
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- ZYME 40.96
- PRTA 24.16
- Support Level
- ZYME $10.86
- PRTA $9.37
- Resistance Level
- ZYME $13.23
- PRTA $8.80
- Average True Range (ATR)
- ZYME 0.56
- PRTA 0.67
- MACD
- ZYME -0.10
- PRTA -0.09
- Stochastic Oscillator
- ZYME 18.78
- PRTA 16.19
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).